Poseida Therapeutics Inc at Stifel Healthcare Conference Transcript
Welcome, everyone. My name is Ben Burnett. Our next session is with Poseida Therapeutics, Mark Gergen, CEO. He's going to give a presentation, and it sounds like there'll be some time for Q&A at the end. So, Mark, thank you for being here.
All right. Thanks. Thanks, Ben. And thanks to the bank for having me. So again, Mark Gergen, I'm the CEO of Poseida Therapeutics.
So at Poseida, we're advancing a new class of cell and gene therapies, ultimately hoping for developing therapies with the capacity to cure. So happy to be here today. We're going to do a quick run-through. We have a lot of technology, so we always invite investors and others to reach out to us. Lot to cover, and we can't probably do justice to it all in the short time we have today.
As always, I'll be making forward-looking statements, so refer you to our SEC filings, including our Qs and Ks for the risks and uncertainties associated in investing in biotech, which I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |